Skip to main content
Premium Trial:

Request an Annual Quote

Genset Decides to Shutter San Diego Facility

NEW YORK, July 16 - French genomics company Genset said today it has decided to shutter its San Diego R&D facility.

 

The space is home to Genset's preclinical metabolic-disorder research group and all its US administrative support, 46 employees in all. The research performed at the facility will be integrated into Genset's space in Evry, France.

 

It was not immediately clear if the San Diego staff was given the option of relocating to Evvry.

 

Genset hinted last month that it might close the facility, a decision that it said coincided with, but did not center on, the firm becoming an acquisition target by Swiss functional-genomics shop Serono.

 

In late June, Serono, based in Geneva, said it planned to buy Genset for €107.4 million, or $106.5 million. Genset's center in Evry will become Serono's worldwide genetics headquarters, and Genset's Paris-based support staff will be transferred to the Evry site.

  

About 20 percent of Genset's workforce of 250 will be laid off. A company representative said last month that the layoffs will be concentrated in administration and support rather than in R&D.

The Scan

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.

Lupus Heterogeneity Highlighted With Single-Cell Transcriptomes

Using single-cell RNA sequencing, researchers in Nature Communications tracked down immune and non-immune cell differences between discoid lupus erythematosus and systemic lupus erythematosus.

Rare Disease Clues Gleaned From Mobile Element Insertions in Exome Sequences

With an approach called MELT, researchers in the European Journal of Human Genetics uncovered mobile element insertions in exomes from 3,232 individuals with or without developmental or neurological abnormalities.

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.